1. Home
  2. Live Updates
  3. Phase 1 2 study nct03564340

Phase 1 2 Study Nct03564340 News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Phase 1 2 study nct03564340 . Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Phase 1 2 Study Nct03564340 Today - Breaking & Trending Today

ADC Advances and Updated PARP Indications Support Focus on Individualized Approaches in Ovarian Cancer

Heather R. Williams, MD, expands on updated data from the the phase 3 PRIMA trial initially supporting the use of frontline PARP inhibitor maintenance in ovarian cancer, as well as changing indications for niraparib based on data from the NOVA trial. ....

United States , Little Rock , University Of Arkansas , Heatherr Williams , Department Of Obstetrics , Division Of Gynecologic Oncology , Institutional Perspectives , Gynecologic Oncology , Medical Sciences , Ovarian Cancer , Recurrent Ovarian Cancer , Uc16xcd3 Bispecific Antibody , Phase 1 2 Study Nct03564340 ,